Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07024563 · ClinicalTrials.gov registry record · Phase 3

Study of Ravulizumab in Pediatric Participants With Primary IgAN

A Phase 3 study of Immunoglobulin A Nephropathy and IgA Vasculitis, sponsored by Alexion Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
24
Enrollment target
14
Study locations

NCT07024563 is a Phase 3 study of Immunoglobulin A Nephropathy and IgA Vasculitis that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 24 participants, below the 303-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (92% lower). The trial reports 14 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07024563, a Phase 3 study of Immunoglobulin A Nephropathy and IgA Vasculitis, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
24 participants
Enrollment target
14
Study locations

Study Summary

The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.

Conditions Studied

Immunoglobulin A Nephropathy IgA Vasculitis IgAN IgAVN Immunoglobulin A Vasculitis Associated Nephritis Henoch-schonlein Purpura Nephritis

Interventions

  • DRUG Ravulizumab

Study Locations (14)

Other

  • Research Site - Beijing
  • Research Site - Shanghai
  • Research Site - Genova
  • Research Site - Roma
  • Research Site - Torino
  • Research Site - Wakayama
  • Research Site - Seoul
  • Research Site - Barcelona
  • Research Site - Barcelona
  • Research Site - Seville
  • Research Site - Taipei
  • Research Site - Taoyuan District

California

  • Research Site - Palo Alto

Colorado

  • Research Site - Aurora

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-06-14
Est. Completion 2029-11-27
Phase Phase 3

Sponsor

Alexion Pharmaceuticals

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07024563

The ClinicalTrials.gov registry entry for NCT07024563 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 303-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (92% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which Ravulizumab is the first listed.

NCT07024563 reports 14 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT07024563 about?

NCT07024563 is a clinical study titled "Study of Ravulizumab in Pediatric Participants With Primary IgAN". The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.

What is the current status of trial NCT07024563?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2025-06-14. Estimated completion is 2029-11-27.

What conditions does trial NCT07024563 study?

This clinical trial studies the following conditions: Immunoglobulin A Nephropathy, IgA Vasculitis, IgAN, IgAVN, Immunoglobulin A Vasculitis Associated Nephritis.

What interventions are being tested in trial NCT07024563?

The interventions under investigation include: Ravulizumab (DRUG).

Who is sponsoring clinical trial NCT07024563?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07024563 being conducted?

This trial has 14 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Immunoglobulin A Nephropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Immunoglobulin A Nephropathy

All registered trials for this condition

IgA Vasculitis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.